97 related articles for article (PubMed ID: 3100491)
1. Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model.
Zinner SH; Dudley MN
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():49-54. PubMed ID: 3100491
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.
Dudley MN; Blaser J; Gilbert D; Mayer KH; Zinner SH
J Infect Dis; 1991 Sep; 164(3):499-506. PubMed ID: 1908000
[TBL] [Abstract][Full Text] [Related]
3. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects.
Orlando PL; Barriere SL; Hindler JA; Frost RW
Diagn Microbiol Infect Dis; 1990; 13(2):93-7. PubMed ID: 2114954
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of subinhibitory concentrations of mezlocillin and azlocillin in blood of patients with chronic lymphatic leukaemia.
Shah PM; Sponheimer T; Stille W
J Chemother; 1989 Jul; 1(4 Suppl):1293-4. PubMed ID: 16312871
[No Abstract] [Full Text] [Related]
5. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
Chalkley LJ; Koornhof HJ
Antimicrob Agents Chemother; 1985 Aug; 28(2):331-42. PubMed ID: 2939797
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.
Johnson M; Miniter P; Andriole VT
J Infect Dis; 1987 Apr; 155(4):783-8. PubMed ID: 3102631
[TBL] [Abstract][Full Text] [Related]
8. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.
Chin NX; Jules K; Neu HC
Eur J Clin Microbiol; 1986 Feb; 5(1):23-8. PubMed ID: 2938945
[TBL] [Abstract][Full Text] [Related]
9. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods.
Zinner SH; Blaser J
J Antimicrob Chemother; 1986 Mar; 17 Suppl A():1-5. PubMed ID: 3086275
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa.
Thauvin C; Lecomte F; Le Boete I; Grise G; Lemeland JF
Infection; 1989; 17(1):31-4. PubMed ID: 2493429
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.
Bustamante CI; Wharton RC; Wade JC
Antimicrob Agents Chemother; 1990 Sep; 34(9):1814-5. PubMed ID: 2126693
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.
Bamberger DM; Peterson LR; Gerding DN; Moody JA; Fasching CE
J Antimicrob Chemother; 1986 Jul; 18(1):51-63. PubMed ID: 3093445
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.
Lagast H; Husson M; Klastersky J
J Antimicrob Chemother; 1985 Sep; 16(3):341-7. PubMed ID: 2932416
[TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activities of azlocillin, ticarcillin and ticarcillin plus clavulanic acid against Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Lagast H; Husson M; Klastersky J
J Antimicrob Chemother; 1985 May; 15(5):633-6. PubMed ID: 3924883
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo action of mezlocillin and azlocillin combined with sisomicin.
Dzierzanowska D; Jeljaszewicz J
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Sep; 255(2-3):346-55. PubMed ID: 6417945
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
Moody JA; Gerding DN; Peterson LR
Am J Med; 1987 Apr; 82(4A):44-54. PubMed ID: 3107380
[TBL] [Abstract][Full Text] [Related]
17. Single daily dosing of amikacin in an in-vitro model.
Dudley MN; Zinner SH
J Antimicrob Chemother; 1991 May; 27 Suppl C():15-9. PubMed ID: 1906862
[TBL] [Abstract][Full Text] [Related]
18. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Grillon A; Schramm F; Kleinberg M; Jehl F
PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
20. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
Tantisiriwat W; Linasmita P
J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
